Comparative Pharmacology
Head-to-head clinical analysis: LANREOTIDE ACETATE versus SANDOSTATIN LAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANREOTIDE ACETATE versus SANDOSTATIN LAR.
LANREOTIDE ACETATE vs SANDOSTATIN LAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lanreotide is a synthetic octapeptide analog of somatostatin. It binds predominantly to somatostatin receptor subtypes 2 (SSTR2) and 5 (SSTR5), inhibiting growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. It also reduces secretion of gastrointestinal hormones such as serotonin and gastrin.
Synthetic octapeptide analog of somatostatin with greater metabolic stability and longer duration of action. Inhibits growth hormone (GH) secretion via binding to somatostatin receptors (SSTR2 and SSTR5) on pituitary somatotrophs. Also suppresses insulin-like growth factor-1 (IGF-1), glucagon, and insulin secretion. Reduces splanchnic blood flow and inhibits secretion of gastrointestinal hormones.
90 mg subcutaneously every 4 weeks
Octreotide acetate 20 mg intramuscularly every 4 weeks for acromegaly; 20 mg intramuscularly every 4 weeks for neuroendocrine tumors; may initiate at 10 mg for symptom control of carcinoid syndrome and dose titrate based on response.
None Documented
None Documented
Terminal elimination half-life: 23-30 hours following subcutaneous administration; prolonged in patients with hepatic or renal impairment.
Terminal half-life: 12-14 days for subcutaneous octreotide LAR microspheres; clinical steady state achieved after 2-3 injections.
Primarily renal (approximately 60-70% of dose excreted unchanged in urine), with biliary/fecal elimination accounting for about 30%.
Renal: 32% as unchanged drug; biliary/fecal: 60-70% via feces as metabolites and unchanged drug.
Category C
Category C
Somatostatin Analog
Somatostatin Analog